The Valley Desk

NCT03822351 · Interventional trial

Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC

Overall registry status Completed

Phase 2

Conditions Stage III Non-small Cell Lung Cancer, Unresectable

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov